LYN and prostate carcinoma: Significantly, inhibition of Lyn in prostate cell lines using a peptide designed to act as a competitive inhibitor of the substrate binding site of the kinase domain, resulted in reduced proliferation not only in vitro but also in mice carrying prostatic cancer xenografts [37].